Dr Kevin Ni
Conjoint Senior Lecturer

Dr Kevin Ni

  • Bachelor of Arts
  • Bachelor of Medicine, Bachelor of Surgery
  • Doctor of Medicine
  • Doctor of Philosophy
Medicine & Health
School of Clinical Medicine

I am a cancer research scientist specialising in molecular biomarker discovery, liquid biopsy and extracellular vesicles, transcriptomics, chemo-/radio-resistance, radiation biology, cancer stem cell and imaging in prostate, breast and bladder cancers.

I am currently a Senior Scientific Officer in Cancer Services at St George Hospital SESLHD and Conjoint Senior Lecturer in School of Clinical Medicine, Faculty of Medicine and Health, based on St George and Sutherland Clinical Campuses.

I obtained my BA and MBBS/MD degrees from China in 2011 and completed my PhD at UNSW Sydney in 2016. To date, I have authored more than 40 publications in peer-reviewed journals which have attracted more than 2,200 citations with an h-index of 25.

Selected Professional & Editorial Activities

  • Contracted Scientific Reviewer, Research Directorate, SESLHD (2021~)
  • Member, Human Research Ethics Committee, SESLHD (2021~)
  • Member, Work Health & Safety Committee, STGCL UNSW (2016~)
  • Member, Peer-Review Taskforce, Postgraduate Scholarships, NHMRC (2020~)
  • Member, Peer-Review Committee, e-Asia joint program, NHMRC (2019)
  • Executive Committee Member, Australian Association for Chinese Biomedical Scientists (2011~)
  • Member, American Association for Cancer Research (2013~)
  • Member, European Association for Cancer Research (2017~)
  • Member, European Society of Medical Oncology (2017~)
  • Associate Editor/Editorial Board Member, Board of Radiation Oncology, Frontiers in Oncology (2020~)
  • Editorial Board Member, Journal of Extracellular Vesicles (2020~)
Phone
(02) 9113 4049
Location
Level 2, Research and Education Centre, St George Hospital, 4-10 South Street, KOGARAH NSW 2217
  • Journal articles | 2021
    Bai X; Ni J; Beretov J; Graham P; Li Y, 2021, 'Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance', Journal of the National Cancer Center, vol. 1, pp. 75 - 87, http://dx.doi.org/10.1016/j.jncc.2021.06.001
    Journal articles | 2021
    Bai X; Ni J; Beretov J; Graham P; Li Y, 2021, 'Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?', Cancer Letters, vol. 497, pp. 100 - 111, http://dx.doi.org/10.1016/j.canlet.2020.10.016
    Journal articles | 2021
    Bai X; Ni J; Beretov J; Wang S; Dong X; Graham P; Li Y, 2021, 'THOC2 and THOC5 Regulate Stemness and Radioresistance in Triple-Negative Breast Cancer', Advanced Science, vol. 8, pp. 2102658 - 2102658, http://dx.doi.org/10.1002/advs.202102658
    Journal articles | 2021
    Bai X; Ni J; Beretov J; Wasinger VC; Wang S; Zhu Y; Graham P; Li Y, 2021, 'Activation of the eIF2 alpha/ATF4 axis drives triple-negative breast cancer radioresistance by promoting glutathione biosynthesis', REDOX BIOLOGY, vol. 43, http://dx.doi.org/10.1016/j.redox.2021.101993
    Journal articles | 2021
    Bai X; Ni J; Beretov J; Wasinger VC; Wang S; Zhu Y; Graham P; Li Y, 2021, 'Activation of the eIF2α/ATF4 axis drives triple-negative breast cancer radioresistance by promoting glutathione biosynthesis', Redox Biology, vol. 43, http://dx.doi.org/10.1016/j.redox.2021.101993
    Journal articles | 2021
    Ni K, 2021, 'Endoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link', Frontiers in Cell and Developmental Biology, http://dx.doi.org/10.3389/fcell.2021.683940
    Journal articles | 2020
    Dong X; Bai X; Ni J; Zhang H; Duan W; Graham P; Li Y, 2020, 'Exosomes and breast cancer drug resistance', Cell Death and Disease, vol. 11, http://dx.doi.org/10.1038/s41419-020-03189-z
    Journal articles | 2020
    Knox MC; Ni J; Bece A; Bucci J; Chin Y; Graham PH; Li Y, 2020, 'A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications', Frontiers in Immunology, vol. 11, http://dx.doi.org/10.3389/fimmu.2020.01612
    Journal articles | 2020
    Ni J; Cheung BB; Beretov J; Duan W; Bucci J; Malouf D; Graham P; Li Y, 2020, 'CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo', Experimental Cell Research, vol. 388, pp. 111850 - 111850, http://dx.doi.org/10.1016/j.yexcr.2020.111850
    Journal articles | 2020
    Pang B; Zhu Y; Ni J; Ruan J; Thompson J; Malouf D; Bucci J; Graham P; Li Y, 2020, 'Quality assessment and comparison of plasma-derived extracellular vesicles separated by three commercial kits for prostate cancer diagnosis', International Journal of Nanomedicine, vol. 15, pp. 10241 - 10256, http://dx.doi.org/10.2147/IJN.S283106
    Journal articles | 2020
    Pang B; Zhu Y; Ni J; Thompson J; Malouf D; Bucci J; Graham P; Li Y, 2020, 'Extracellular vesicles: The next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis', Theranostics, vol. 10, pp. 2309 - 2326, http://dx.doi.org/10.7150/thno.39486
    Journal articles | 2020
    Wang J; Ni J; Beretov J; Thompson J; Graham P; Li Y, 2020, 'Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer', Critical Reviews in Oncology/Hematology, vol. 145, pp. 102860 - 102860, http://dx.doi.org/10.1016/j.critrevonc.2019.102860
    Journal articles | 2019
    Chang L; Ni J; Zhu Y; Pang B; Graham P; Zhang H; Li Y, 2019, 'Liquid biopsy in ovarian cancer: Recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression', Theranostics, vol. 9, pp. 4130 - 4140, http://dx.doi.org/10.7150/thno.34692
    Journal articles | 2019
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y, 2019, 'Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression', BMC Cancer, vol. 19, http://dx.doi.org/10.1186/s12885-019-5824-9
    Journal articles | 2019
    Feng X; Bai X; Ni J; Wasinger VC; Beretov J; Zhu Y; Graham P; Li Y, 2019, 'CHTOP in chemoresistant epithelial ovarian cancer: A novel and potential therapeutic target', Frontiers in Oncology, vol. 9, http://dx.doi.org/10.3389/fonc.2019.00557
    Journal articles | 2019
    Ni J; Bongers A; Chamoli U; Bucci J; Graham P; Li Y, 2019, 'In Vivo 3D MRI Measurement of Tumour Volume in an Orthotopic Mouse Model of Prostate Cancer', Cancer Control, vol. 26, pp. 1073274819846590, http://dx.doi.org/10.1177/1073274819846590
    Journal articles | 2019
    Ni J; Bucci J; Malouf D; Knox M; Graham P; Li Y, 2019, 'Exosomes in Cancer Radioresistance', Frontiers in Oncology, vol. 9, http://dx.doi.org/10.3389/fonc.2019.00869
    Journal articles | 2019
    Tsao T; Beretov J; Ni J; Bai X; Bucci J; Graham P; Li Y, 2019, 'Cancer stem cells in prostate cancer radioresistance', Cancer Letters, vol. 465, pp. 94 - 104, http://dx.doi.org/10.1016/j.canlet.2019.08.020
    Journal articles | 2018
    Bai X; Ni J; Beretov J; Graham P; Li Y, 2018, 'Cancer stem cell in breast cancer therapeutic resistance', Cancer Treatment Reviews, vol. 69, pp. 152 - 163, http://dx.doi.org/10.1016/j.ctrv.2018.07.004
    Journal articles | 2018
    Ni J; Cozzi P; Beretov J; Duan W; Bucci J; Graham P; Li Y, 2018, 'Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo', BMC Cancer, vol. 18, pp. 1092, http://dx.doi.org/10.1186/s12885-018-5010-5
    Journal articles | 2017
    Chang L; Ni J; Beretov J; Wasinger VC; Hao J; Bucci J; Malouf D; Gillatt D; Graham PH; Li Y, 2017, 'Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach', Scientific Reports, vol. 7, http://dx.doi.org/10.1038/srep41834
    Journal articles | 2017
    Ni J; Bucci J; Chang L; Malouf D; Graham P; Li Y, 2017, 'Targeting microRNAs in prostate cancer radiotherapy', Theranostics, vol. 7, pp. 3243 - 3259, http://dx.doi.org/10.7150/thno.19934
    Journal articles | 2017
    Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y, 2017, 'Urinary biomarkers in prostate cancer detection and monitoring progression', Critical Reviews in Oncology/Hematology, vol. 118, pp. 15 - 26, http://dx.doi.org/10.1016/j.critrevonc.2017.08.002
    Journal articles | 2016
    Chang L; Graham P; Hao J; Ni J; Deng J; Bucci J; Malouf D; Gillatt D; Li Y, 2016, 'Cancer stem cells and signaling pathways in radioresistance', Oncotarget, vol. 7, pp. 11002 - 11017, http://dx.doi.org/10.18632/oncotarget.6760
    Journal articles | 2016
    Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y, 2016, 'Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer', Oncotarget, vol. 7, pp. 55771 - 55788, http://dx.doi.org/10.18632/oncotarget.9908
    Journal articles | 2016
    Deng J; Wang L; Ni J; Beretov J; Wasinger V; Wu D; Duan W; Graham P; Li Y, 2016, 'Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy', Expert Review of Proteomics, vol. 13, pp. 905 - 915, http://dx.doi.org/10.1080/14789450.2016.1233065
    Journal articles | 2016
    Hao J; Graham P; Chang L; Ni J; Wasinger V; Beretov J; Deng J; Duan W; Bucci J; Malouf D; Gillatt D; Li Y, 2016, 'Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy', Oncotarget, vol. 7, pp. 74269 - 74285, http://dx.doi.org/10.18632/oncotarget.12368
    Journal articles | 2016
    Ni J; Cozzi P; Hung T; Hao J; Graham PH; Li Y, 2016, 'Monitoring Prostate Tumor Growth in an Orthotopic Mouse Model Using Three-Dimensional Ultrasound Imaging Technique', Translational Oncology, vol. 9, pp. 41 - 45, http://dx.doi.org/10.1016/j.tranon.2015.11.011
    Journal articles | 2015
    Chang L; Graham P; Hao J; Bucci J; Malouf D; Gillatt D; Li Y, 2015, 'Proteomics discovery of radioresistant cancer biomarkers for radiotherapy', Cancer Letters, vol. 369, pp. 289 - 297, http://dx.doi.org/10.1016/j.canlet.2015.09.013
    Journal articles | 2015
    Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y, 2015, 'Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance', Critical Reviews in Oncology/Hematology, vol. 96, pp. 507 - 517, http://dx.doi.org/10.1016/j.critrevonc.2015.07.005
    Journal articles | 2014
    Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2014, 'PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways', Cell Death and Disease, vol. 5, http://dx.doi.org/10.1038/cddis.2014.415
    Journal articles | 2014
    Lei C; Wasinger V; Graham P; Hao J; Ni J; Beretov J; Bucci J; Cozzi P; Kearsley J; Li Y, 2014, 'THE USE OF LABEL-FREE LC-MS/MS APPROACH TO IDENTIFY SIGNALING PATHWAYS ASSOCIATED WITH PROSTATE CANCER RADIORESISTANCE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol. 10, pp. 130 - 130, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2014
    Ni J; Cozzi P; Hao J; Duan W; Graham P; Kearsley J; Li Y, 2014, 'Cancer stem cells in prostate cancer chemoresistance', Current Cancer Drug Targets, vol. 14, pp. 225 - 240, http://dx.doi.org/10.2174/1568009614666140328152459
    Journal articles | 2014
    Ni J; Cozzi PJ; Hao JL; Beretov J; Chang L; Duan W; Shigdar S; Delprado WJ; Graham PH; Bucci J; Kearsley JH; Li Y, 2014, 'CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance', The Prostate, vol. 74, pp. 602 - 617, http://dx.doi.org/10.1002/pros.22775
    Journal articles | 2013
    Chang L; Graham P; Hao J; Ni J; Bucci J; Cozzi P; Kearseley J; Li Y, 2013, 'PI3K/Akt/mTOR dual inhibitors have an advantage over single inhibitors in overcoming prostate cancer radioresistance.', MOLECULAR CANCER THERAPEUTICS, vol. 12, http://dx.doi.org/10.1158/1535-7163.TARG-13-A283
    Journal articles | 2013
    Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2013, 'Acquisition of epithelialmesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance', Cell Death and Disease, vol. 4, http://dx.doi.org/10.1038/cddis.2013.407
    Journal articles | 2013
    Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y, 2013, 'The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression', Cancer and Metastasis Reviews, vol. 32, pp. 535 - 551, http://dx.doi.org/10.1007/s10555-013-9423-y
    Journal articles | 2013
    Hao J; Ni J; Cozzi PJ; Graham PH; Bucci J; Kearsley J; Li Y, 2013, 'The CD44 Isoforms in Prostate Cancer Metastasis and progression', World Journal of Cancer Research, vol. 1, pp. 3 - 14, http://dx.doi.org/10.1166/wjcr.2013.1009
    Journal articles | 2013
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y, 2013, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway', International Journal of Biochemistry and Cell Biology, vol. 45, pp. 2736 - 2748, http://dx.doi.org/10.1016/j.biocel.2013.09.008
    Journal articles | 2013
    Xiao W; Graham PH; Hao J; Chang L; Ni J; Power CA; Dong Q; Kearsley JH; Li Y, 2013, 'Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0074253
    Journal articles | 2022
    Lee N; Canagasingham A; Bajaj M; Shanmugasundaram R; Hutton A; Bucci J; Graham P; Thompson J; Ni J, 2022, 'Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: From functional roles to clinical significance', Frontiers in Oncology, vol. 12, http://dx.doi.org/10.3389/fonc.2022.1019391
  • Conference Papers | 2020
    Bai X; Ni J; Li Y; Beretov J, 2020, 'Abstract 6163: Integrated stress response contributes to triple negative breast cancer radioresistance by regulating glutathione biosynthesis', in Cancer Research, American Association for Cancer Research (AACR), pp. 6163 - 6163, presented at Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA, http://dx.doi.org/10.1158/1538-7445.am2020-6163
    Conference Papers | 2019
    Bai X; Feng X; Ni J; Beretov J; Deng J; Zhu Y; Graham P; Li Y, 2019, 'Abstract 4754: CHTOP is a novel therapeutic target for chemoresistant epithelial ovarian cancer therapy', in Cancer Research, American Association for Cancer Research (AACR), pp. 4754 - 4754, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.am2019-4754
    Conference Abstracts | 2019
    Bai X; Feng X; Ni J; Beretov J; Deng J; Zhu Y; Graham P; Li Y, 2019, 'CHTOP is a novel therapeutic target for chemoresistant epithelial ovarian cancer therapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-4754
    Conference Papers | 2018
    Ni J; Cozzi P; Beretov J; Bucci J; Graham P; Li Y, 2018, 'Study of CD44 variant 6 (CD44v6) in prostate cancer chemo-/radio resistance in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-1999
    Conference Abstracts | 2017
    Ni J; Cozzi P; Beretov J; Bucci J; Graham P; Li Y, 2017, 'Studying CD44 variant 6 (CD44v6) in prostate cancer progression and chemo-/radio-resistance using in vivo mouse models', in Annals of Oncology, OXFORD UNIV PRESS, Singapore, SINGAPORE, Vol. 28, pp. x78 - x79, presented at ESMO Asia Congress, Singapore, SINGAPORE, 17 November 2017 - 19 November 2017, http://dx.doi.org/10.1093/annonc/mdx662.006
    Conference Papers | 2017
    Ni J; Cozzi P; Beretov J; Deng J; Bucci J; Graham P; Li Y, 2017, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer progression and chemo/radio-resistance in vitro and in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-2833
    Conference Abstracts | 2015
    Hao J; Graham P; Chang L; Ni J; Beretov J; Deng J; Bucci J; Cozzi P; Li Y, 2015, 'Combination of LBH589 and radiotherapy overcomes radioresistance in radioresistant prostate cancer cells in vitro and animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Cairns, Vol. 116, pp. 33 - 34, presented at 2nd Prostate Cancer World Congress (PCWC), AUSTRALIA, Cairns, 17 August 2015 - 21 August 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2015
    Hao J; Graham PH; Chang L; Ni J; Wasinger V; Beretov J; Bucci J; Cozzi P; Li Y, 2015, 'Identification of lactate dehydrogenase A (LDHA) as a potential therapeutic target for prostate cancer radiotherapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-2001
    Conference Abstracts | 2015
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Deng J; Duan W; Graham P; Bucci J; Li Y, 2015, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer chemo-/radio-resistance in cell lines in vitro and in animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Cairns, Vol. 116, pp. 31 - 31, presented at 2nd Prostate Cancer World Congress (PCWC), AUSTRALIA, Cairns, 17 August 2015 - 21 August 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Presentations | 2015
    Ni K, 2015, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer chemo-/radio-resistance in cell lines in vitro and in animal models in vivo.', presented at 2nd Prostate Cancer World Congress, Cairns, QLD, Australia, 17 August 2015 - 21 August 2015
    Conference Papers | 2014
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Delprado W; Graham P; Bucci J; Kearsley J; Li Y, 2014, 'CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/beta-catenin signaling pathways in vitro', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-4005
    Conference Abstracts | 2014
    Ni K, 2014, 'CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signalling pathways in vitro.', in CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signalling pathways in vitro., AACR 2014, presented at AACR 2014
    Conference Abstracts | 2013
    Ni K, 2013, 'CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression.', in CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression., LOWY cancer symposium, presented at LOWY cancer symposium
    Conference Abstracts | 2013
    Ni K, 2013, 'CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression.', in CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression., The St George & Sutherland Medical Research Symposium, presented at The St George & Sutherland Medical Research Symposium
    Conference Presentations | 2012
    Chang L; Peter G; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley J; Li Y; Hao J, 2012, 'Epithelial mesenchymal transition (EMT) is involved in the prostate cancer radiation resistance.', Vol. 8, pp. 333 - 333, presented at IPOS 14th World Congress and COSA's 39th Annual Scientific Meeting, Brisbane, Australia, 13 November 2012 - 15 November 2012, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400351&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
    Conference Presentations | 2012
    Ni K, 2012, 'EpCAM (CD326) and CD44 variants are biomarkers associated with prostate cancer metastasis and progression.', presented at The St George & Sutherland Medical Research Symposium, 11 October 2012 - 11 October 2012
    Conference Abstracts | 2012
    Ni K, 2012, 'Over-expression of EpCAM (CD326) and CD44 variants in human prostate cancer cells are potential therapeutic targets for targeted therapy.', in Over-expression of EpCAM (CD326) and CD44 variants in human prostate cancer cells are potential therapeutic targets for targeted therapy., 13th Australasian Prostate Cancer Conference, presented at 13th Australasian Prostate Cancer Conference
    Conference Abstracts | 2022
    Katelaris A; Canagasingham A; Ni J; Deshpande N; Malouf D; Bucci J; Thompson J; Bai X; Pang B; Zhu Y; Wilkins M; Graham P; Li Y, 2022, 'Isolation of exosomal microRNA to serve as a diagnostic biomarker for prostate cancer: A provisional analysis of 12 patients', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 140 - 140, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200227&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

  • CIA: A novel liquid biopsy assay of blood exosomal microRNA profiles to improve prostate cancer diagnosis. St George and Sutherland Medical Research Foundation, A$46,000, 2021-2022;
  • AI: Combining nanoplasmonic profiling with machine learning for non-invasive early detection of ovarian cancer using plasma exosomes, Ovarian Cancer Research Foundation (GA-2019-13), A$134,026, 2020-2021.
  • CI: Validation of extracellular vesicle protein biomarkers in blood for the personalised treatment decision of prostate cancer patients. SSMRF-St George Cancer Care Foundation Award, A$50,000, 2022-2023.

  • National Scholarship of Excellence, 2008;
  • Outstanding Graduate, 2011;
  • Prostate and Breast Cancer Foundation Scholarships, 2012-2015;
  • Outstanding Self-financed Students Abroad Award of China, 2013;
  • Best oral presentation in Basic Science, 2nd Prize, St George and Sutherland Medical Research Symposium, 2016;
  • Travel grant award, European Society for Medical Oncology (ESMO) Asia 2017 Congress, 2017;
  • Service Excellence Award, AACBS, 2018.

Dr Ni's current research interests are

  • identification of biomarkers in liquid biopsy (exosomes) on early detection and prognostic evaluation of prostate cancer patients;
  • proteomic and transcriptomic identification of novel biomarkers to predict radio-resistance in breast and prostate cancers;
  • investigation of the mechanisms of cancer progression, metastasis and therapeutic resistance associated with tumour microenvironment and cancer stem cells;
  • clinicopathologic and biomarker predictors for bladder cancer diagnosis, prognosis and surveillance.

https://www.theleader.com.au/story/5759719/scientists-pave-the-way-forward-with-medical-research/

St George Hospital cancer researchers work to advance benefits for patients through early detection

My Research Supervision

  • PhD students 2x (EV transcriptomics and metabolomics in prostate cancer)
  • Masters Student 1x (EV proteomics in breast cancer)
  • Hons students 1x (primary supervisor, with peer-reviewed publication, EV miRNAs in bladder cancer)
  • Incoming Hons student Year 2023 2x (EV and MRI in prostate and bladder cancers)